As part of our series focussing on new medicines available in Australia, we have added a product review of the use of lebrikizumab for the management of moderate-to-severe atopic dermatitis.
This review discusses indications and dosage, contraindications and a series of clinical studies featuring lebrikizumab use to treat atopic dermatitis. It provides commentary from Associate Professor John Frew, clinical dermatologist, director of research at the Skin Hospital in Darlinghurst and associate professor of dermatology at UNSW.
Please login below to download this issue (PDF)